304 related articles for article (PubMed ID: 25360671)
1. Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia.
Sheehan VA; Crosby JR; Sabo A; Mortier NA; Howard TA; Muzny DM; Dugan-Perez S; Aygun B; Nottage KA; Boerwinkle E; Gibbs RA; Ware RE; Flanagan JM
PLoS One; 2014; 9(10):e110740. PubMed ID: 25360671
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.
Ware RE; Despotovic JM; Mortier NA; Flanagan JM; He J; Smeltzer MP; Kimble AC; Aygun B; Wu S; Howard T; Sparreboom A
Blood; 2011 Nov; 118(18):4985-91. PubMed ID: 21876119
[TBL] [Abstract][Full Text] [Related]
3. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
4. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.
Estepp JH; Smeltzer MP; Kang G; Li C; Wang WC; Abrams C; Aygun B; Ware RE; Nottage K; Hankins JS
Am J Hematol; 2017 Dec; 92(12):1333-1339. PubMed ID: 28913922
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia.
Walker AL; Steward S; Howard TA; Mortier N; Smeltzer M; Wang YD; Ware RE
Blood; 2011 Nov; 118(20):5664-70. PubMed ID: 21921042
[TBL] [Abstract][Full Text] [Related]
6. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
Quinn CT; Niss O; Dong M; Pfeiffer A; Korpik J; Reynaud M; Bonar H; Kalfa TA; Smart LR; Malik P; Ware RE; Vinks AA; McGann PT
Br J Haematol; 2021 Aug; 194(3):617-625. PubMed ID: 34227124
[TBL] [Abstract][Full Text] [Related]
7. Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
Green NS; Barral S
Pediatr Res; 2014 Jan; 75(1-2):196-204. PubMed ID: 24252885
[TBL] [Abstract][Full Text] [Related]
8. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE
Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791
[TBL] [Abstract][Full Text] [Related]
9. Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.
Green NS; Ender KL; Pashankar F; Driscoll C; Giardina PJ; Mullen CA; Clark LN; Manwani D; Crotty J; Kisselev S; Neville KA; Hoppe C; Barral S
PLoS One; 2013; 8(2):e55709. PubMed ID: 23409025
[TBL] [Abstract][Full Text] [Related]
10. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.
Ballas SK; Connes P;
Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261
[TBL] [Abstract][Full Text] [Related]
11. Fetal hemoglobin levels in African American and Hispanic children with sickle cell disease at baseline and in response to hydroxyurea.
Ender KL; Lee MT; Sheth S; Licursi M; Crotty J; Barral S; Green NS
J Pediatr Hematol Oncol; 2011 Oct; 33(7):496-9. PubMed ID: 21941141
[TBL] [Abstract][Full Text] [Related]
12. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
[TBL] [Abstract][Full Text] [Related]
13. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.
Green NS; Barral S
Pediatr Blood Cancer; 2011 Feb; 56(2):177-81. PubMed ID: 20830771
[TBL] [Abstract][Full Text] [Related]
14. Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia.
Schaefer BA; Flanagan JM; Alvarez OA; Nelson SC; Aygun B; Nottage KA; George A; Roberts CW; Piccone CM; Howard TA; Davis BR; Ware RE
PLoS One; 2016; 11(10):e0164364. PubMed ID: 27711207
[TBL] [Abstract][Full Text] [Related]
15. Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea.
Nottage KA; Ware RE; Winter B; Smeltzer M; Wang WC; Hankins JS; Dertinger SD; Shulkin B; Aygun B
Eur J Haematol; 2014 Nov; 93(5):377-83. PubMed ID: 24796940
[TBL] [Abstract][Full Text] [Related]
16. Fetal hemoglobin in sickle cell anemia: The Arab-Indian haplotype and new therapeutic agents.
Habara AH; Shaikho EM; Steinberg MH
Am J Hematol; 2017 Nov; 92(11):1233-1242. PubMed ID: 28736939
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological modification of hemoglobin F expression in sickle cell anemia: an update on hydroxyurea studies.
Charache S
Experientia; 1993 Feb; 49(2):126-32. PubMed ID: 7680002
[TBL] [Abstract][Full Text] [Related]
18. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
Ma Q; Wyszynski DF; Farrell JJ; Kutlar A; Farrer LA; Baldwin CT; Steinberg MH
Pharmacogenomics J; 2007 Dec; 7(6):386-94. PubMed ID: 17299377
[TBL] [Abstract][Full Text] [Related]
19. The role of BCL11A and HMIP-2 polymorphisms on endogenous and hydroxyurea induced levels of fetal hemoglobin in sickle cell anemia patients from southern Brazil.
Friedrisch JR; Sheehan V; Flanagan JM; Baldan A; Summarell CC; Bittar CM; Friedrisch BK; Wilke II; Ribeiro CB; Daudt LE; da Rocha Silla LM
Blood Cells Mol Dis; 2016 Nov; 62():32-37. PubMed ID: 27838552
[TBL] [Abstract][Full Text] [Related]
20. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
